Exelixis, Inc. (EXEL) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
EXEL Revenue Growth
Revenue Breakdown (FY 2025)
EXEL's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
EXEL Revenue Analysis (2014–2025)
As of May 6, 2026, Exelixis, Inc. (EXEL) generated trailing twelve-month (TTM) revenue of $2.38 billion, reflecting solid growth of +10.0% year-over-year. The most recent quarter (Q1 2026) recorded $610.8 million in revenue, up 2.0% sequentially.
Looking at the longer-term picture, EXEL's 5-year compound annual growth rate (CAGR) stands at +18.6%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $2.32 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows EXEL's business is primarily driven by Product, Gross (65%), Product (46%), and License (5%). With over half of revenue concentrated in Product, Gross, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including INCY (+21.5% YoY), ALKS (-5.2% YoY), and JAZZ (+9.2% YoY), EXEL has underperformed the peer group in terms of revenue growth. Compare EXEL vs INCY →
EXEL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| EXELCurrent | $2.4B | +10.0% | +18.6% | 37.6% | |
 INCY | $5.1B | +21.5% | +14.0% | 26.1% | |
 ALKS | $1.5B | -5.2% | +7.3% | 17.2% | |
 JAZZ | $4.3B | +9.2% | +12.5% | 5.3% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
EXEL Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.32B | +7.0% | $2.24B | 96.4% | $872.2M | 37.6% |
| 2024 | $2.17B | +18.5% | $2.09B | 96.5% | $604.6M | 27.9% |
| 2023 | $1.83B | +13.6% | $1.76B | 96.0% | $170.9M | 9.3% |
| 2022 | $1.61B | +12.3% | $1.55B | 96.4% | $201.5M | 12.5% |
| 2021 | $1.43B | +45.3% | $1.38B | 96.3% | $286.7M | 20.0% |
| 2020 | $987.5M | +2.0% | $951.3M | 96.3% | $110.1M | 11.1% |
| 2019 | $967.8M | +13.3% | $934.7M | 96.6% | $369.5M | 38.2% |
| 2018 | $853.8M | +88.7% | $827.5M | 96.9% | $438.9M | 51.4% |
| 2017 | $452.5M | +136.3% | $437.4M | 96.7% | $165.9M | 36.7% |
| 2016 | $191.5M | +415.0% | $184.9M | 96.6% | $-28,124,000 | -14.7% |
Full EXEL Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See EXEL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs EXEL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare EXEL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonEXEL — Frequently Asked Questions
Quick answers to the most common questions about buying EXEL stock.
Is EXEL's revenue growth accelerating or slowing?
EXEL maintains +10.0% revenue growth, in line with its 5-year CAGR of +18.6%. TTM revenue stands at $2.4B. Growth rate remains consistent with historical average.
What is EXEL's long-term revenue growth rate?
Exelixis, Inc.'s 5-year revenue CAGR of +18.6% reflects the sustained expansion pattern. Current YoY growth of +10.0% is near this long-term average.
How is EXEL's revenue distributed by segment?
EXEL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.